These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23205907)

  • 1. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
    Horazeck C; Huh AS; Huh BK
    Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.
    Prusik J; Argoff C; Peng S; Pilitsis JG
    Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term intrathecal ziconotide for chronic pain: an open-label study.
    Webster LR; Fisher R; Charapata S; Wallace MS
    J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment.
    Bäckryd E; Sörensen J; Gerdle B
    Neuromodulation; 2015 Jul; 18(5):404-13. PubMed ID: 25879804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Term Outcomes of a High-Volume, Low-Concentration Bolus Starting Dose Technique With Ziconotide: A Case Series.
    Lindley D
    Neuromodulation; 2021 Oct; 24(7):1209-1214. PubMed ID: 34252245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.
    Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR
    Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.
    Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W
    Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziconotide for spinal cord injury-related pain.
    Brinzeu A; Berthiller J; Caillet JB; Staquet H; Mertens P
    Eur J Pain; 2019 Oct; 23(9):1688-1700. PubMed ID: 31233255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal ziconotide for refractory chronic pain.
    Lynch SS; Cheng CM; Yee JL
    Ann Pharmacother; 2006; 40(7-8):1293-300. PubMed ID: 16849624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up.
    Hayek SM; Hanes MC; Wang C; Veizi IE
    Neuromodulation; 2015 Jul; 18(5):397-403. PubMed ID: 25655991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.